Archive | Company Profiles RSS feed for this section

ThermoFisher (TMO) : Growth or Value?

Is there anybody who does not like ThermoFisher (TMO)stock? Thermofisher (TMO) has more fans than U2, Lady GaGa and Rihanna combined. Why is that? We are trying to find out.TMO is a life science tools conglomerate with revenues of $10.8B and Net Income of $1.036B for 2010. They are financial engineers adept at M&A, buying […]

Comments Off Continue Reading →

Innovation Drives Market Gains in Biopharmaceuticals

This article was published in Genetic Engineering News in the section “Wall Street Biobeat” on April 1, 2011. Monoclonal antibody therapies remain the dominant technology with immunotherapy and stem cell therapies on the horizon. GEN | Articles: Innovations Continue to Drive Market Gains Emerging Technologies in Biomedicine-Continuing Series Published in Genetic Engineering News April 1 […]

Comments Off Continue Reading →

Reporting from the JPMorgan 29th Annual Healthcare Conference 2011

J.P.Morgan 29th Annual Healthcare Conference San Francisco, CA January 9-13 2011 Biotechnology: Bright Prospects For 2011 Rod Raynovich The J.P.Morgan Healthcare Conference was a hot ticket in a cold city with over 8500 attendees at the St.Francis Westin Hotel. Topcoats were the unlikely fashion trend due to below normal temps (30’s). Some people complained about […]

Comments Off Continue Reading →

Vermillion Soars on a Quiet Day: VRML $9 Up 23.2%

Vermillion (VRML) continues its wild ride upward from the November low of $4.53 on heavy volume of 546K shares with no apparent news. Two analysts cover the stock with a buy/outperform and Revenue Forecasts in the $7M range for Year Ending Dec.’11 and a Price Target of 10. The market cap is $93M. The stock price […]

Comments Off Continue Reading →

Vermillion(VRML):Novel Diagnostic Tests Utilizing Biomarkers

Restructuring Play in Diagnostics at a VC Valuation Vermilion(VRML) technology utilizes a panel of biomarkers integrated with multivariate analysis software to develop disease specific assays. The R&D effort leverages collaborations with institutions such as Stanford, John Hopkins and MD Anderson for discovery and validation of biomarkers. Vermillion’s OVA 1 Test for ovarian cancer was cleared […]

Comments Off Continue Reading →

Cardiovascular Systems (CSII) Gains Traction-Good Value Play

Cardiovascular Systems(CSII) is a medical device Company that focuses on interventional treatment for peripheral arterial disease(PAD). The primary products are  the Diamondback 360 and the Predator 360,  minimally invasive catheter systems for a range of plaque types in leg arteries.PAD blockages in leg arteries can lead to pain,immobility, non-healing wounds and eventual loss of limbs […]

Comments Off Continue Reading →